Drug Profile
Fadraciclib - Cyclacel Pharmaceuticals
Alternative Names: CYC-065Latest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator Cyclacel Pharmaceuticals
- Class Amines; Antineoplastics; Purines; Pyridines; Small molecules
- Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Leukaemia; Lymphoma; Myelodysplastic syndromes; Solid tumours
- Preclinical T-cell prolymphocytic leukaemia
- No development reported Neuroblastoma
Most Recent Events
- 06 Feb 2024 Cyclacel Pharmaceuticals suspends a phase I/II trials in Myelodysplastic syndromes (Monotherapy, Refractory metastatic disease, Second-line therapy or greater) and Leukaemia in USA (PO) due to slow enrollment and financial limitations (NCT05168904)
- 18 Dec 2023 Efficacy and adverse events data from a Phase-I/II clinical trials in Solid tumours released by Cyclacel Pharmaceuticals
- 09 Dec 2023 Preclinical trials in T-cell prolymphocytic leukaemia in USA (unspecified route), prior to December 2023